Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. A common first-line therapy offered to qualifying patients includes ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase. Treatment of CLL with ibrutinib therapy is generally well tolerated; how...
| Published in: | Case Reports in Hematology |
|---|---|
| Main Authors: | Ensi Voshtina, Huiya Huang, Renju Raj, Ehab Atallah |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2018/6514604 |
Similar Items
Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)
by: EA Stadnik, et al.
Published: (2018-01-01)
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)
by: EA Nikitin, et al.
Published: (2017-07-01)
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
by: Candida Vitale, et al.
Published: (2016-06-01)
by: Candida Vitale, et al.
Published: (2016-06-01)
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01)
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
by: Javier Rey-Barroso, et al.
Published: (2023-06-01)
by: Javier Rey-Barroso, et al.
Published: (2023-06-01)
Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)
by: Ayşe Kaya, et al.
Published: (2024-03-01)
The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)
by: NV Kurkina, et al.
Published: (2019-05-01)
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
by: Koh Okamoto, et al.
Published: (2016-01-01)
by: Koh Okamoto, et al.
Published: (2016-01-01)
Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
by: Ramsay Hafer, et al.
Published: (2025-02-01)
by: Ramsay Hafer, et al.
Published: (2025-02-01)
Granulomatous amebic encephalitis caused by Acanthamoeba in an immuncompetent child
by: Murat Sütçü, et al.
Published: (2018-06-01)
by: Murat Sütçü, et al.
Published: (2018-06-01)
Challenges and advances in the medical treatment of granulomatous amebic encephalitis
by: Natasha Spottiswoode, et al.
Published: (2024-02-01)
by: Natasha Spottiswoode, et al.
Published: (2024-02-01)
Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
by: EA Dmitrieva, et al.
Published: (2019-09-01)
by: EA Dmitrieva, et al.
Published: (2019-09-01)
Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Pierre Stéphan, et al.
Published: (2024-08-01)
by: Pierre Stéphan, et al.
Published: (2024-08-01)
FRAILTY ASSESSMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE COMBINATION OF VENETOCLAX AND IBRUTINIB
by: TX Carneiro, et al.
Published: (2023-10-01)
by: TX Carneiro, et al.
Published: (2023-10-01)
EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)
by: T. V. SOROKINA, et al.
Published: (2017-06-01)
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)
by: Anıl Tombak, et al.
Published: (2021-12-01)
Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report
by: Zhenhui Lv, et al.
Published: (2025-09-01)
by: Zhenhui Lv, et al.
Published: (2025-09-01)
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
by: Xue Yi, et al.
Published: (2022-02-01)
by: Xue Yi, et al.
Published: (2022-02-01)
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib
by: Cecelia R. Miller, et al.
Published: (2017-08-01)
by: Cecelia R. Miller, et al.
Published: (2017-08-01)
P654: IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH COMPLEX KARYOTYPE AND CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. Petrenko, et al.
Published: (2022-06-01)
by: A. Petrenko, et al.
Published: (2022-06-01)
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program
by: Peter Hillmen, et al.
Published: (2018-05-01)
by: Peter Hillmen, et al.
Published: (2018-05-01)
Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
by: Larissa Lane Cardoso Teixeira, et al.
Published: (2022-07-01)
by: Larissa Lane Cardoso Teixeira, et al.
Published: (2022-07-01)
Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
by: Anna-Eve Turcotte, et al.
Published: (2023-01-01)
by: Anna-Eve Turcotte, et al.
Published: (2023-01-01)
Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy
by: Stefano Molica, et al.
Published: (2025-07-01)
by: Stefano Molica, et al.
Published: (2025-07-01)
Experimental Granulomatous Amebic Encephalitis Caused by <i>Acanthamoeba castellanii</i>
by: Samuel da Luz Borges, et al.
Published: (2024-06-01)
by: Samuel da Luz Borges, et al.
Published: (2024-06-01)
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
by: Gülşen İskender, et al.
Published: (2020-08-01)
by: Gülşen İskender, et al.
Published: (2020-08-01)
BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)
by: Lorenzo Falchi, et al.
Published: (2016-02-01)
A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia
by: William Paul Skelton IV, et al.
Published: (2016-01-01)
by: William Paul Skelton IV, et al.
Published: (2016-01-01)
RAPID REDUCTION OF LYMPH NODE ENLARGEMENT IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB
by: JOR Cassiano, et al.
Published: (2023-10-01)
by: JOR Cassiano, et al.
Published: (2023-10-01)
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)
by: Isacco Ferrarini, et al.
Published: (2022-04-01)
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
by: Kerry A. Rogers, et al.
Published: (2021-03-01)
by: Kerry A. Rogers, et al.
Published: (2021-03-01)
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
by: Stefania Fiorcari, et al.
Published: (2021-03-01)
by: Stefania Fiorcari, et al.
Published: (2021-03-01)
Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study
by: Jelena Ivanovic, et al.
Published: (2025-08-01)
by: Jelena Ivanovic, et al.
Published: (2025-08-01)
Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
by: Anna Christoforidou, et al.
Published: (2018-05-01)
by: Anna Christoforidou, et al.
Published: (2018-05-01)
Mathematical multi-compartment modeling of chronic lymphocytic leukemia cell kinetics under ibrutinib
by: Melanie Schulz, et al.
Published: (2024-12-01)
by: Melanie Schulz, et al.
Published: (2024-12-01)
Recurrent Fibrillary Glomerulonephritis Secondary to Chronic Lymphocytic Leukemia: Remission of Kidney Disease with Ibrutinib
by: Rafeea Shah, et al.
Published: (2024-10-01)
by: Rafeea Shah, et al.
Published: (2024-10-01)
Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
by: Julio Delgado, et al.
Published: (2019-04-01)
by: Julio Delgado, et al.
Published: (2019-04-01)
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia
by: Richárd Kiss, et al.
Published: (2019-01-01)
by: Richárd Kiss, et al.
Published: (2019-01-01)
Exploring the mechanism of amebic trogocytosis: the role of amebic lysosomes
by: Allissia A. Gilmartin, et al.
Published: (2017-12-01)
by: Allissia A. Gilmartin, et al.
Published: (2017-12-01)
Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
by: Simge Erdem, et al.
Published: (2024-03-01)
by: Simge Erdem, et al.
Published: (2024-03-01)
Similar Items
-
Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01) -
Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01) -
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
by: Candida Vitale, et al.
Published: (2016-06-01) -
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
by: Keisuke Kidoguchi, et al.
Published: (2021-02-01) -
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
by: Javier Rey-Barroso, et al.
Published: (2023-06-01)
